Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Type 2 diabetes is a chronic condition characterized by the body's inability to properly utilize insulin. Individuals with type 2 diabetes either do not produce enough insulin or their body becomes resistant to the action of insulin. It is often referred to as adult-onset diabetes because it commonly develops in middle-aged or older adults, although it can occur at any age.
Symptoms of type 2 diabetes include:
Type 2 diabetes can lead to various complications, including:
Management of type 2 diabetes typically involves lifestyle modifications such as a healthy diet, regular exercise, and weight management. Medications, including oral medications and insulin therapy, may also be prescribed to help control blood sugar levels. Monitoring blood sugar levels regularly and managing other risk factors such as high blood pressure and high cholesterol are essential in preventing complications associated with type 2 diabetes. Regular medical check-ups and adherence to treatment plans are crucial for effectively managing the condition and reducing the risk of complications.
Empatab 10mg Tablet should be used with caution in patients with a history of alcoholism. Consult your doctor before taking it.
Empatab 10mg Tablet is generally not recommended for use in pregnant women as it is unknown if it is harmful to the unborn child. Consult your doctor before taking it.
It is not known if Empatab 10mg Tablet passes through breast milk. Consult your doctor before taking it.
Empatab 10mg Tablet has no or negligible effect on the ability to drive or use machines. Consult your doctor if you feel any side effects during management that may stop you from driving or using machines.
Empatab 10mg Tablet should be taken with caution in patients with kidney problems. Consult your doctor before taking it.
Empatab 10mg Tablet should be taken with caution in patients with liver problems. Consult your doctor before taking it.
Type 2 diabetes mellitus
Empatab 10 blocks the sodium-glucose co-transporter-2 (SGLT-2) enzyme in the kidney's proximal tubules. It lowers renal reabsorption of glucose and increases urine excretion of glucose via inhibiting SGLT2. As a result, it lowers blood sugar levels in diabetics.
Common adverse reactions include urinary tract infections, female genital mycotic infections, dehydration, hypotension, weakness, dizziness, and increased thirst.
Empatab 10mg Tablet plays a vital role in managing diabetes and achieving good control of blood sugar levels by delaying the absorption of sugar and increasing insulin sensitivity in the body.
Empagliflozin acts as a sodium-glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters facilitate glucose reabsorption from the kidney filtrate. Inhibiting SGLT2 reduces renal glucose absorption, lowers the renal threshold for glucose, increases glucose excretion, and contributes to reduced hyperglycemia, weight loss, and decreased blood pressure.
The recommended dose is 10 mg once daily, in the morning, with or without food. If tolerated, the dose may be increased to 25 mg once daily. Correcting volume depletion before initiating Empagliflozin is recommended.
In case of overdose, supportive measures should be employed. Empagliflozin removal by hemodialysis has not been studied.
Empagliflozin may interact with diuretics, insulin, or insulin secretagogues, potentially increasing urine volume or the risk of hypoglycemia. It also affects urine glucose tests and 1,5-anhydroglucitol (1,5-AG) assay reliability.
Empagliflozin is contraindicated in patients with severe hypersensitivity reactions to the drug or its components, severe renal impairment, end-stage renal disease, or undergoing dialysis.
Use during pregnancy is only recommended if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding due to unknown excretion in human milk.
Renal function should be assessed before initiating Empagliflozin and periodically thereafter. It should not be initiated if eGFR is less than 45 ml/min/1.73 m2.
Store below 30°C in a cool, dry place, protected from light and moisture, and keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.